Current and historical daily PE Ratio for Swedish Orphan Biovitrum AB (
LTS:0MTD
) from 2010 to May 16 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Swedish Orphan Biovitrum AB stock (LTS:0MTD) PE ratio as of May 16 2024 is 45.45.
More Details
Swedish Orphan Biovitrum AB (LTS:0MTD) PE Ratio (TTM) Chart
Swedish Orphan Biovitrum AB (LTS:0MTD) PE Ratio (TTM) Historical Data
View and export this data going back to 2010. Start your Free Trial
Total 1253
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Swedish Orphan Biovitrum AB PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-16 | 45.5 | 2024-03-11 | 38.1 |
| 2024-05-15 | 45.5 | 2024-03-08 | 37.8 |
| 2024-05-14 | 44.2 | 2024-03-07 | 36.8 |
| 2024-05-13 | 44.9 | 2024-03-06 | 36.4 |
| 2024-05-10 | 45.0 | 2024-03-05 | 36.0 |
| 2024-05-09 | 44.5 | 2024-03-04 | 35.2 |
| 2024-05-08 | 44.5 | 2024-03-01 | 35.5 |
| 2024-05-07 | 44.5 | 2024-02-29 | 34.3 |
| 2024-05-03 | 44.4 | 2024-02-28 | 34.5 |
| 2024-05-02 | 44.4 | 2024-02-27 | 34.5 |
| 2024-05-01 | 44.5 | 2024-02-26 | 34.6 |
| 2024-04-30 | 44.5 | 2024-02-23 | 35.5 |
| 2024-04-29 | 44.5 | 2024-02-22 | 35.8 |
| 2024-04-26 | 44.1 | 2024-02-21 | 35.9 |
| 2024-04-25 | 44.5 | 2024-02-20 | 35.7 |
| 2024-04-24 | 42.1 | 2024-02-19 | 35.0 |
| 2024-04-23 | 41.9 | 2024-02-16 | 34.3 |
| 2024-04-22 | 41.4 | 2024-02-15 | 34.3 |
| 2024-04-19 | 41.1 | 2024-02-14 | 33.4 |
| 2024-04-18 | 41.1 | 2024-02-13 | 33.9 |
| 2024-04-17 | 40.3 | 2024-02-12 | 34.0 |
| 2024-04-16 | 40.8 | 2024-02-09 | 34.5 |
| 2024-04-15 | 40.2 | 2024-02-08 | 34.9 |
| 2024-04-12 | 39.8 | 2024-02-07 | 38.0 |
| 2024-04-11 | 40.4 | 2024-02-06 | 38.0 |
| 2024-04-10 | 40.8 | 2024-02-05 | 36.9 |
| 2024-04-09 | 41.9 | 2024-02-02 | 36.7 |
| 2024-04-08 | 41.3 | 2024-02-01 | 37.4 |
| 2024-04-05 | 41.7 | 2024-01-31 | 39.5 |
| 2024-04-04 | 41.2 | 2024-01-30 | 39.5 |
| 2024-04-03 | 41.4 | 2024-01-29 | 39.3 |
| 2024-04-02 | 41.8 | 2024-01-26 | 38.7 |
| 2024-03-28 | 42.5 | 2024-01-25 | 38.9 |
| 2024-03-27 | 36.4 | 2024-01-24 | 38.9 |
| 2024-03-26 | 36.1 | 2024-01-23 | 38.4 |
| 2024-03-25 | 36.4 | 2024-01-22 | 39.5 |
| 2024-03-22 | 36.5 | 2024-01-19 | 39.4 |
| 2024-03-21 | 36.5 | 2024-01-18 | 38.9 |
| 2024-03-20 | 36.0 | 2024-01-17 | 38.5 |
| 2024-03-19 | 35.6 | 2024-01-16 | 39.2 |
| 2024-03-18 | 36.0 | 2024-01-15 | 38.4 |
| 2024-03-15 | 36.6 | 2024-01-12 | 39.3 |
| 2024-03-14 | 37.5 | 2024-01-11 | 39.0 |
| 2024-03-13 | 38.0 | 2024-01-10 | 37.6 |
| 2024-03-12 | 38.0 | 2024-01-09 | 38.0 |
Swedish Orphan Biovitrum AB (LTS:0MTD) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Swedish Orphan Biovitrum AB
ISIN : SE0000872095
Compare
Compare
Traded in other countries / regions
SOBI.Sweden0MTD.UKSWOBY.USAB6E.GermanySOBI.Mexico IPO Date
2010-04-09Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers